17 alpha-hydroxyprogesterone caproate has been researched along with medroxyprogesterone acetate in 25 studies
| Studies (17 alpha-hydroxyprogesterone caproate) | Trials (17 alpha-hydroxyprogesterone caproate) | Recent Studies (post-2010) (17 alpha-hydroxyprogesterone caproate) | Studies (medroxyprogesterone acetate) | Trials (medroxyprogesterone acetate) | Recent Studies (post-2010) (medroxyprogesterone acetate) |
|---|---|---|---|---|---|
| 517 | 88 | 251 | 5,123 | 1,115 | 1,099 |
| Protein | Taxonomy | 17 alpha-hydroxyprogesterone caproate (IC50) | medroxyprogesterone acetate (IC50) |
|---|---|---|---|
| Estrogen receptor | Homo sapiens (human) | 0.924 | |
| Glucocorticoid receptor | Homo sapiens (human) | 0.013 | |
| Progesterone receptor | Homo sapiens (human) | 2.5081 | |
| Glycine receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | 0.019 | |
| Mineralocorticoid receptor | Homo sapiens (human) | 1.197 | |
| Androgen receptor | Homo sapiens (human) | 0.0061 | |
| Androgen receptor | Rattus norvegicus (Norway rat) | 0.279 | |
| Glycine receptor subunit beta | Rattus norvegicus (Norway rat) | 0.019 | |
| Glycine receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | 0.019 | |
| Glycine receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | 0.019 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 1.197 | |
| Aldo-keto reductase family 1 member C3 | Homo sapiens (human) | 1.4059 | |
| Aldo-keto reductase family 1 member C2 | Homo sapiens (human) | 4.0405 | |
| Aldo-keto reductase family 1 member C1 | Homo sapiens (human) | 1.8 | |
| Estrogen receptor beta | Homo sapiens (human) | 0.924 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (32.00) | 18.7374 |
| 1990's | 5 (20.00) | 18.2507 |
| 2000's | 9 (36.00) | 29.6817 |
| 2010's | 3 (12.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kollman, PA; Lee, DL; Marsh, FJ; Wolff, ME | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Titova, VA; Voznyĭ, EK | 1 |
| Bobrov, IuF; Bokhman, IaV; Fel'dkoren, BI; Tsyrlina, EV; Vishnevskiĭ, AS | 1 |
| Ashkenazy, M; Czernobilsky, B; Kessler, I; Lancet, M; Nahshoni, A | 1 |
| Fujimoto, J; Fujita, H; Nakata, Y; Okada, H | 1 |
| Roopnarinesingh, S | 1 |
| Bauer, J; Papez, L | 1 |
| Das Gupta, V | 1 |
| Sang, GW | 1 |
| Koetsawang, S | 1 |
| Giwa-Osagie, OF | 1 |
| Jarvis, G; Kitchener, H; Lilford, R; Martin-Hirsch P, L | 1 |
| Adamian, RT | 1 |
| Charkviani, L; Charkviani, T; Kobiashvili, H | 1 |
| Izutsu, T; Sugiyama, T | 1 |
| Aoki, D; Banno, K; Nozawa, S; Susumu, N; Suzuki, A; Suzuki, N; Tamada, Y | 1 |
| Delke, I; Kaunitz, AM; Sanchez-Ramos, L | 1 |
| Elovitz, MA; Mrinalini, C | 1 |
| Caritis, S; Mada, SR; Mattison, D; Sharma, S; Torch, M; Venkataramanan, R; Zhang, S | 1 |
| Huo, Z; Lang, JH; Shen, K; Wu, M; Yang, JX; Yu, M | 1 |
| Brockbank, E; Bryant, A; Gallagher, C; Kokka, F; Oram, D | 1 |
| Allen, TK; Buhimschi, IA; Feng, L; Grotegut, CA; Murtha, AP; Nazzal, M | 1 |
9 review(s) available for 17 alpha-hydroxyprogesterone caproate and medroxyprogesterone acetate
| Article | Year |
|---|---|
Pharmacodynamic effects of once-a-month combined injectable contraceptives.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Algestone Acetophenide; China; Contraceptive Agents, Female; Contraceptives, Oral, Combined; Delayed-Action Preparations; Drug Combinations; Estradiol; Female; Humans; Hydroxyprogesterones; Injections, Intramuscular; Latin America; Medroxyprogesterone Acetate; Norethindrone | 1994 |
Once-a-month injectable contraceptives: efficacy and reasons for discontinuation.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Algestone Acetophenide; Clinical Trials, Phase III as Topic; Contraceptive Agents, Female; Contraceptives, Oral, Combined; Delayed-Action Preparations; Drug Combinations; Estradiol; Female; Humans; Hydroxyprogesterones; Injections, Intramuscular; Medroxyprogesterone Acetate; Multicenter Studies as Topic; Norethindrone; Randomized Controlled Trials as Topic | 1994 |
Metabolic effects of once-a-month combined injectable contraceptives. The World Health Organization Task Force on Long-Acting Systemic Agents for Fertility Regulation, Geneva, Switzerland.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Algestone Acetophenide; Carbohydrate Metabolism; Contraceptive Agents, Female; Estradiol; Female; Hemostasis; Humans; Hydroxyprogesterones; Injections; Lipid Metabolism; Medroxyprogesterone Acetate; Norethindrone | 1994 |
Facts about once-a-month injectable contraceptives: memorandum from a WHO meeting.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Animals; Contraceptive Agents, Female; Contraceptives, Oral, Combined; Delayed-Action Preparations; Drug Combinations; Drug Evaluation; Estradiol; Estrogen Antagonists; Estrogens, Conjugated (USP); Female; Humans; Hydroxyprogesterones; Injections, Intramuscular; Medroxyprogesterone Acetate; Norethindrone; World Health Organization | 1993 |
Progestagens for endometrial cancer.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Endometrial Neoplasms; Female; Humans; Hydroxyprogesterones; Medroxyprogesterone Acetate; Progestins | 2000 |
[Hormone therapy for uterine corpus cancer--introduction].
Topics: 17 alpha-Hydroxyprogesterone Caproate; Antineoplastic Agents, Hormonal; Endometrial Neoplasms; Estrogens; Female; Gonadotropin-Releasing Hormone; Humans; Hydroxyprogesterones; Leuprolide; Medroxyprogesterone Acetate; Raloxifene Hydrochloride; Receptors, Progesterone; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome | 2004 |
[Conservative hormonal therapy for endometrial cancer].
Topics: 17 alpha-Hydroxyprogesterone Caproate; Antineoplastic Agents, Hormonal; Endometrial Neoplasms; Female; Humans; Hydroxyprogesterones; Medroxyprogesterone Acetate; Megestrol Acetate; Neoplasm Recurrence, Local; Neoplasm Staging; Treatment Outcome | 2004 |
Progestational agents to prevent preterm birth: a meta-analysis of randomized controlled trials.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adolescent; Adult; Confidence Intervals; Female; Follow-Up Studies; Gestational Age; Humans; Hydroxyprogesterones; Incidence; Medroxyprogesterone Acetate; Odds Ratio; Pregnancy; Pregnancy Outcome; Pregnancy, High-Risk; Premature Birth; Prenatal Care; Randomized Controlled Trials as Topic; Reference Values; Risk Assessment; Treatment Outcome | 2005 |
Hormonal therapy in advanced or recurrent endometrial cancer.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Antineoplastic Agents, Hormonal; Disease-Free Survival; Drug Therapy, Combination; Endometrial Neoplasms; Female; Humans; Hydroxyprogesterones; Medroxyprogesterone Acetate; Megestrol; Neoplasm Recurrence, Local; Neoplasm Staging; Progestins | 2010 |
2 trial(s) available for 17 alpha-hydroxyprogesterone caproate and medroxyprogesterone acetate
| Article | Year |
|---|---|
Acceptability of drugs for male fertility regulation: a prospectus and some preliminary data. World Health Organization Task Force on Psychosocial Research in Family Planning.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Clinical Trials as Topic; Contraceptive Agents, Male; Contraceptive Devices, Male; Cyproterone; Cyproterone Acetate; Humans; Hydroxyprogesterones; Libido; Male; Medroxyprogesterone; Medroxyprogesterone Acetate; Sexual Behavior; Testosterone; Vasectomy; World Health Organization | 1980 |
[Therapy of atypical hyperplasia and adenocarcinoma of the endometrium with the combination of progestins and anticoagulants].
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adenocarcinoma; Anticoagulants; Antineoplastic Agents, Hormonal; Drug Therapy, Combination; Endometrial Neoplasms; Endometrium; Estrogen Antagonists; Female; Humans; Hydroxyprogesterones; Hyperplasia; Medroxyprogesterone Acetate; Neoplasm Staging; Progesterone Congeners; Treatment Outcome | 2001 |
14 other study(ies) available for 17 alpha-hydroxyprogesterone caproate and medroxyprogesterone acetate
| Article | Year |
|---|---|
Quantitative relationships between steroid structure and binding to putative progesterone receptors.
Topics: Androstenes; Animals; Guinea Pigs; Humans; Hydroxyprogesterones; Protein Binding; Rabbits; Receptors, Progesterone; Sheep; Steroids; Structure-Activity Relationship | 1977 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
[Progestins in combined treatment of endometrial cancer].
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Drug Therapy, Combination; Estrogen Antagonists; Female; Humans; Hydroxyprogesterones; Medroxyprogesterone; Medroxyprogesterone Acetate; Middle Aged; Progestins; Uterine Neoplasms | 1990 |
[Effect of progestin therapy on the level of cytoplasmic receptors in patients with cancer of the corpus uteri].
Topics: 17 alpha-Hydroxyprogesterone Caproate; Antineoplastic Agents; Cytoplasm; Drug Evaluation; Female; Homeostasis; Humans; Hydroxyprogesterones; Lymphatic Metastasis; Medroxyprogesterone; Medroxyprogesterone Acetate; Middle Aged; Preoperative Care; Receptors, Cell Surface; Reproduction; Uterine Neoplasms; Vaginal Smears | 1989 |
Ovarian tumors in pregnancy.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Abortion, Spontaneous; Adult; Combined Modality Therapy; Female; Humans; Hydroxyprogesterones; Medroxyprogesterone; Medroxyprogesterone Acetate; Ovarian Neoplasms; Ovariectomy; Pregnancy; Pregnancy Complications, Neoplastic | 1988 |
[Hormone dependency and progestogen therapy in the treatment of endometrial cancer].
Topics: 17 alpha-Hydroxyprogesterone Caproate; Cell Division; Female; Humans; Hydroxyprogesterones; Medroxyprogesterone; Medroxyprogesterone Acetate; Neoplasms, Hormone-Dependent; Norethindrone; Tamoxifen; Tumor Stem Cell Assay; Uterine Neoplasms | 1987 |
Evaluation of progestational agents for postmenopausal hot flushes.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Climacteric; Double-Blind Method; Female; Humans; Hydroxyprogesterones; Medroxyprogesterone; Medroxyprogesterone Acetate; Middle Aged; Progesterone Congeners | 1982 |
[Prevention of dysfunctional metrorrhagia in the climacteric].
Topics: 17 alpha-Hydroxyprogesterone Caproate; Climacteric; Clomiphene; Female; Humans; Hydroxyprogesterones; Medroxyprogesterone; Medroxyprogesterone Acetate; Metrorrhagia; Middle Aged | 1983 |
Quantitation of hydroxyprogesterone caproate, medroxyprogesterone acetate, and progesterone by reversed-phase high-pressure liquid chromatography.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Chromatography, High Pressure Liquid; Drug Stability; Hydroxyprogesterones; Medroxyprogesterone; Medroxyprogesterone Acetate; Progesterone; Suspensions; Tablets | 1982 |
Organ preserving method in the management of atypical endometrial hyperplasia.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Oral; Adult; Endometrial Hyperplasia; Female; Humans; Hydroxyprogesterones; Injections, Intramuscular; Medroxyprogesterone; Medroxyprogesterone Acetate; Middle Aged; Pregnancy; Progesterone Congeners | 2001 |
The use of progestational agents for preterm birth: lessons from a mouse model.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Animals; C-Reactive Protein; Female; Hydroxyprogesterones; Interleukin-10; Interleukin-6; Lipopolysaccharides; Medroxyprogesterone Acetate; Mice; Models, Animal; Pregnancy; Premature Birth; Progestins | 2006 |
Simultaneous quantitation of 17alpha-hydroxyprogesterone caproate, 17alpha-hydroxyprogesterone and progesterone in human plasma using high-performance liquid chromatography-mass spectrometry (HPLC-MS/MS).
Topics: 17 alpha-Hydroxyprogesterone Caproate; Chromatography, High Pressure Liquid; Drug Stability; Female; Humans; Hydroxyprogesterones; Medroxyprogesterone Acetate; Methanol; Pregnancy; Progesterone; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Solid Phase Extraction; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Water | 2008 |
Fertility-preserving treatment in young women with well-differentiated endometrial carcinoma and severe atypical hyperplasia of endometrium.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Antineoplastic Agents, Hormonal; Cell Differentiation; Combined Modality Therapy; Endometrial Neoplasms; Endometrium; Female; Fertility; Follow-Up Studies; Humans; Hydroxyprogesterones; Hyperplasia; Infertility, Female; Medroxyprogesterone Acetate; Megestrol Acetate; Progestins; Remission Induction; Reproductive Techniques, Assisted; Retrospective Studies; Severity of Illness Index | 2009 |
The Effect of Progestins on Tumor Necrosis Factor α-Induced Matrix Metalloproteinase-9 Activity and Gene Expression in Human Primary Amnion and Chorion Cells In Vitro.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Amnion; Cells, Cultured; Chorion; Female; Gene Expression Regulation, Enzymologic; Humans; Hydroxyprogesterones; Matrix Metalloproteinase 9; Medroxyprogesterone Acetate; Pregnancy; Progesterone; Progestins; RNA, Messenger; Tumor Necrosis Factor-alpha | 2015 |